Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 6c ; Offers Guidance

Amneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.19, $0.06 better than the analyst estimate of $0.13. Revenue for the quarter came in at $620.04 million versus the consensus estimate of $590.62 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 EPS of $0.51-$0.58, versus the consensus of $0.57. Amneal Pharmaceuticals sees FY2023 revenue of $2.37-2.42 billion, versus the consensus of $2.4 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates